Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Given Consensus Rating of “Moderate Buy” by Brokerages

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) has received an average recommendation of “Moderate Buy” from the twelve ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $54.90.

Several research firms have issued reports on FTH. Zacks Research raised shares of Sensei Biotherapeutics to a “hold” rating in a research report on Tuesday, April 21st. Citizens Jmp started coverage on shares of Sensei Biotherapeutics in a report on Monday, July 20th. They set an “outperform” rating and a $51.00 target price on the stock. Raymond James Financial initiated coverage on Sensei Biotherapeutics in a research note on Friday, July 31st. They issued an “outperform” rating and a $56.00 target price on the stock. Citigroup began coverage on Sensei Biotherapeutics in a report on Friday, May 22nd. They set a “buy” rating and a $55.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th.

Insider Buying and Selling

In other news, CFO Brian C. Stephenson purchased 9,391 shares of the company’s stock in a transaction on Wednesday, June 24th. The shares were acquired at an average price of $26.13 per share, for a total transaction of $245,386.83. Following the purchase, the chief financial officer owned 26,804 shares in the company, valued at $700,388.52. This trade represents a 53.93% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Anand Kiran Parikh acquired 2,806 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was purchased at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the completion of the acquisition, the chief executive officer directly owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 49,494 shares of company stock worth $1,188,822 in the last 90 days. Insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On Sensei Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FTH. Renaissance Technologies LLC boosted its position in Sensei Biotherapeutics by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after purchasing an additional 1,100 shares in the last quarter. Bank of America Corp DE boosted its holdings in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares during the last quarter. Stempoint Capital LP purchased a new stake in Sensei Biotherapeutics during the 1st quarter worth approximately $4,188,000. Finally, Vivo Capital LLC acquired a new position in shares of Sensei Biotherapeutics during the first quarter valued at approximately $22,758,000. 10.50% of the stock is owned by institutional investors and hedge funds.

Sensei Biotherapeutics Price Performance

Shares of Sensei Biotherapeutics stock opened at $24.59 on Thursday. The company has a market capitalization of $32.95 million, a PE ratio of -0.17 and a beta of -0.25. Sensei Biotherapeutics has a one year low of $7.20 and a one year high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last released its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter. As a group, research analysts forecast that Sensei Biotherapeutics will post -15.23 earnings per share for the current year.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.